CN1357620A - Hemapoietic stem/ancestral cell enriching method and its in vitro directional induction and differentiation - Google Patents
Hemapoietic stem/ancestral cell enriching method and its in vitro directional induction and differentiation Download PDFInfo
- Publication number
- CN1357620A CN1357620A CN 01141866 CN01141866A CN1357620A CN 1357620 A CN1357620 A CN 1357620A CN 01141866 CN01141866 CN 01141866 CN 01141866 A CN01141866 A CN 01141866A CN 1357620 A CN1357620 A CN 1357620A
- Authority
- CN
- China
- Prior art keywords
- cell
- differentiation
- marrow
- enrichment
- hemapoietic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The present invention obtains enriched human hemapoietic stem/ancestral cell through a two-step negative enriching process according to the different physical and chemical properties of cell components in umbilical cord blood and by means of the nylon fiber adsorption to B lymphocyte and the plastic product adsorption of monocyte/macrophages. It can preserve the late stage ancestral cell and hemapoietic cell component, so that the present invention provides a practical way for clinical in vitro induction and differentiation of cell for prepairng hemapoietic damage. The in vitro directional induction and differentiation experiment shows that the cell may be induced and differentiated directionally to erythrocytic series and granulocyte series.
Description
The present invention relates to a kind of hemocyte physico-chemical property of utilizing, the method for two-step approach negativity enrichment hematopoietic stem reaches cells in vitro directional induction differentiation and the purposes in the hematopoiesis injury repairing thereof in enrichment under this condition.
Hemopoietic stem cell (HSC) relies on the ability of its powerful self and polyphyly differentiation and keeps the relative constant state with of body hematopoiesis place, and continues all one's life.Therefore, HSC is considered to carry out hemopoietic tissue and transplants the key component that the back rebuilds long-term hematopoiesis and immunologic function, and is optimal target cell in the gene therapy of some disease.Thereby how effectively isolating hematopoietic stem cells is the focus of hematology research field all the time, and this makes the research of hemopoietic stem cell phenotype seem particularly important.In recent years, the foundation of the discovery of hematopoietic cell sorting technology, hemopoieticgrowth factor and clone, various ex vivo operative techniquies and perfect, make hematopoietic cell be easier to operation and use in the transformation of quantity, performance and function aspects, thereby emerging research and Application Areas have been produced, i.e. the hematopoietic cell engineering.The hematopoietic cell engineering is to utilize the height multiplication capacity and the multidirectional differentiation potential of hematopoietic stem, technology by cell engineering, in in-vitro simulated or intravital hematopoiesis environment of partial simulation or process, hematopoietic stem to separation and purification is carried out amplification in vitro, the directional induction differentiation, function activation and regulation and control, goal gene transfection etc., thereby the hemopoietic progenitor cell that a large amount of at short notice amplifications are early stage and the hemopoietic forebody cell in each stage, and a large amount of red corpuscle of directional induction amplification, grain/scavenger cell, megalokaryocyte/thrombocyte, dendritic cell, the NK cell, functioning cell and immunologically competent cells such as T/B lymphocyte, and can the function of part cell be activated and regulate and control, the defective gene is carried out the target transfection, and hematopoietic cell is treated more extensive and is effectively applied to stem cell transplantation the most at last, the biological immune treatment, fields such as hematopoiesis supportive treatment and gene therapy.The application of hematopoietic cell engineering has two bases, and the one, the separation of precursor cell (because the growth of the meta-bolites of mature cell meeting pair cell in the vitro culture process produces very adverse influence), the 2nd, the application of vitro culture system.
Cell therapy is a kind of high-tech biotherapy means that develop rapidly is in the last few years got up, and it is the important component part of biological immune treatment and gene therapy.Hemocyte is owing to the function with multiple complexity such as transportation oxygen, reparation damage endothelium, control infection, participation immunity of organism, so it is again the topmost cell of cell therapy source.
People utilize different combination of cytokines, hematopoietic stem is broken up to different directions according to our requirement, thereby produce our the required cellular product that is used for clinical treatment.So-called third generation cell therapy scheme that Here it is (first-generation therapy is the complete blood cell infusion, second on behalf of be the hematopoietic stem cell transplantation of representative with the bone marrow transplantation), this method at first is a spot of CD34 of separation and purification
+Or its subgroup hematopoietic stem (CD34
+CD38
+, CD34
+CD38
-, CD34
+HLA-DR
+, CD34
+HLA-DR
-Deng), utilize the potential of its height multiplication capacity and multidirectional differentiation, increase and the directional induction differentiation external, thereby produce a large amount of early progenitor cells and the hemocyte in each stage at short notice, and immunologically competent cell such as a large amount of neutrophil leucocyte of directed expansion, red corpuscle, thrombocyte, dendritic cell, NK cell, be widely used in field (Scheding S such as hematopoietic stem cell transplantation, knubble biological immunotherapy, hematopoiesis supportive treatment and gene therapy the most at last, et al.Exp Hematol, 2000; 28:460.Hino M, et al.Br J Haematol.2000; 109:314.).
Mostly the method that in the past was used to separate hematopoietic stem is to utilize immunomagnetic beads to carry out purifying, though the cell that obtains is purer, but increased expense on the one hand, on the other hand owing to adopt the isolating method of positivity, the cell surface that is obtained all has magnetic bead, this is that clinical application institute is unallowed, and more priorly be, cell behind the purifying has often been removed the progenitor cell and the useful cellular constituent of pair cell vitro culture of many directed differentiation, this is unaccommodated for clinical application, our invention is to explore and a kind ofly can be applicable to the method for clinical separation hematopoietic stem and make it external evokedly be divided into clinical required cellular constituent, thereby is applied to the reparation of hematopoiesis damage.
Content of the present invention is unexposed to be delivered, and those skilled in the art can not obtain separation method of the present invention according to existing technology deduction as not spending creative work at all.
The method that the purpose of this invention is to provide a kind of enrichment hematopoietic stem is so that the external mature cell that differentiates function of efficiently inducing is to be applied to basis and clinical.
The combination of materials that is used for cell enrichment of the present invention is nylon cotton column and plastic culture plate.
By to the separation of Cord blood mononuclearcell and utilize studies show that of directional induction in vitro differentiation, flow cytometry analysis of this method isolated cells, the isolated cell of the present invention institute can differentiate red system and grain is a cell external efficiently inducing.The content of CD34+ cell can reach more than 30% and (only contain less than 1% in the mononuclearcell) in the cell after the enrichment.
With embodiment the present invention is further elaborated below.
The separation of embodiment 1. Cord blood mononuclearcells
One method
1. the bleeding of the umbilicus of anticoagulant heparin (from Yongding Lu hospital) is in 1: 1 ratio and PBS mixing, and by 4: 1 and 0.5% methylcellulose gum mixing, room temperature left standstill 30 minutes, treated that the red corpuscle natural subsidence is clearly demarcated to boundary again.
2. the sucking-off supernatant places the 50ml centrifuge tube, centrifugal 5 minutes of 20 ℃, 1500rpm.
3. abandon supernatant, add the 5mlPBS re-suspended cell.
4. add earlier the 5ml lymphocyte separation medium in the 10ml centrifuge tube, slowly add the 5ml cell suspension along tube wall again, centrifugal 20 minutes of 20 ℃, 1500rpm are isolated mononuclearcell.
5. collect the interface mononuclearcell, wash with PBS.
6. with PBS suspension cell counting, standby.
Annotate: above operation is all in strict accordance with the aseptic technique rules
Two. the result
Can from Cord blood, isolate (8.465 ± 4.04) * 10 through aforesaid method
7Individual mononuclearcell.
Embodiment 2. utilizes the bone-marrow-derived lymphocyte in the nylon face post removal cell
One, the preparation of method () nylon cotton column: 1 removes cotton about 10 grams of nylon, is filament (thin more good more) with fine it is torn of hand; Soaked 2 hours with 1% dilute hydrochloric acid afterwards.2 collect the nylon cotton, clean with distilled water and dry.3 join the nylon cotton in the injector syringe of 10ml, and high pressure steam sterilization is standby.(2) cellular segregation: 1 takes out nylon cotton column, is suspended on the shelf, connects three joint pistons down, earlier with PBS washing 3 times.2 closure pistons add the mononuclearcell that suspends with nutrient solution, join uniformly in the nylon cotton column, make the liquid level of cell suspension be lower than the interface of nylon cotton.3 are positioned over 37 ℃ with nylon cotton column, hatch 1 hour.4 take out nylon cotton column, place in the super clean bench.The bottle that a sterilization is put in the post lower end is used for collecting cell, pipettes the lid on the post, adds damping fluid (PBS that contains 5%FBS) from styletable, and it is swept away with the cell that gravity will not attach on the nylon column.5 continue to add damping fluid, up to the liquid of collecting 3 times of column volumes.6 with cell centrifugation, and the cell of collection is the cell suspension of having removed bone-marrow-derived lymphocyte.Annotate: above operation is all in strict accordance with the aseptic technique rules
Two results
By the aforesaid method ratio that isolated Lin-cell accounts for mononuclearcell from Cord blood is (60.6 ± 10.31) %; The cell absolute number is: (4.95 ± 2.42) * 10
7
The removal of embodiment 3. Monocytes
One. method 1 is added to the cell of aforesaid method results in the IMDM nutrient solution, is seeded in the disposable plastic culturing bottle, hatches 2 hours for 37 ℃.2 collect not adherent cell.
Two. the result
The ratio that the hematopoietic stem of enrichment accounts for single nuclear-cell is: 29.05 ± 8.16%, and the cell absolute number is: (8.42 ± 4.53) * 10
6
The CD34+ cell content of the hematopoietic stem of embodiment 4. enrichments is analyzed
One. method
Cell directly with the tally counting, behind the PBS washed cell, adds with the FITC-CD34 monoclonal antibody in the cell suspension of PBS suspension, hatched on ice 30 minutes, and washed cell, flow cytometer detects (Coulter).Establish the negative control antibody of FITC-IgG1 mark simultaneously.
Two. the result
The content of CB34+ cell increases gradually with its content of carrying out in each step, finally is 32%.
The hematopoietic stem of embodiment 5. enrichments is that cell directional is induced differentiation to red system and grain
One. method
1. cell cultures
Contain SCF100ng/ml in IMDM (Gibco company) substratum, TPO 4U/ml, IL-6100ng/ml, IL-3 100ng/ml, EPO 2U/ml (is that the directional induction differentiation changes EPO into G-CSF100ng/ml to grain).The hematopoietic stem inoculum density of enrichment is 5 * 105/ml, at 37 ℃, 5%CO
2Cultivate under the condition, half amount is changed liquid weekly, and per 3 days additional above-mentioned substances once.Collect the part cell in the 7th day and the 14th day and be used for cell counting and cell phenotype analysis.
2. cell counting and cell surface marker analysis
Cell directly with the tally counting, behind the PBS washed cell, is used PE-CD11b, and the PE-GlycophorinA monoclonal antibody adds in the cell suspension of PBS suspension, hatched on ice 30 minutes, and washed cell, flow cytometer detects (Coulter).Establish the negative control antibody of PE-IgG1 and FITC-IgG1 mark simultaneously.
Three. the result
The hematopoietic stem of enrichment is under above-mentioned cell culture condition, and total cellular score can increase 35 ± 2.75 times at the 7th day that cultivates, and total cellular score can increase 94.5 ± 12.96 times in 14 days, can increase 456 ± 34.26 times in 21 days.The flow cytometer detected result shows that CD11b+ (granulocytic surface marker) and Glycophorin A+ cell (erythroid cells surface marker) ratio can reach more than 60% and (sees accompanying drawing).
Figure of description 1 is depicted as: the variation a negative control b of CD34+ cell expressing amount removes from the isolating mononuclearcell c of Cord blood that Figure of description 2 is depicted as after d removes Monocytes behind the B cell in the cell enrichment process: to red be directional induction differentiation back red be that the expression Figure of description 3 of surface marker is depicted as: to grain is that directional induction differentiation back grain is the expression of surface marker
Claims (4)
1. the method for an enrichment artificial blood ancestral cells is characterized in that utilizing the physico-chemical property of mature cell, adopts the isolating method enrichment of negativity hematopoietic stem.
2. according to the cell isolation method of claim 1, it is characterized in that utilizing earlier bone-marrow-derived lymphocyte can with the characteristic of the cotton absorption of nylon, do in order to the bone-marrow-derived lymphocyte in the removal sample sample and nylon are cotton.
3. according to the separation method of the cell of claim 1, after it is characterized in that removing bone-marrow-derived lymphocyte, utilize Monocytes to stick to characteristic on the culture dish again, the sample of removing bone-marrow-derived lymphocyte is hatched in nutrient solution, remove Monocytes, thereby reach the purpose of enrichment hematopoietic stem.
4. by claim 2, the isolated cell of 3 separation methods is in external scheme of carrying out the directional induction differentiation, it is characterized in that utilizing different combination of cytokines to differentiate hemocyte, be expected to be applied to the reparation of hematopoiesis damage external inducing in a large number with function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011418664A CN100506978C (en) | 2001-09-21 | 2001-09-21 | Hemapoietic stem/ancestral cell enriching method and its in vitro directional induction and differentiation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011418664A CN100506978C (en) | 2001-09-21 | 2001-09-21 | Hemapoietic stem/ancestral cell enriching method and its in vitro directional induction and differentiation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1357620A true CN1357620A (en) | 2002-07-10 |
| CN100506978C CN100506978C (en) | 2009-07-01 |
Family
ID=4676453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011418664A Expired - Lifetime CN100506978C (en) | 2001-09-21 | 2001-09-21 | Hemapoietic stem/ancestral cell enriching method and its in vitro directional induction and differentiation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100506978C (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104862278A (en) * | 2014-02-26 | 2015-08-26 | 苏州方舟基因药业有限公司 | Isolated human hematopoietic stem cell amplification culture solution formula |
| CN105254717A (en) * | 2015-08-18 | 2016-01-20 | 广州一代医药科技有限公司 | Polypeptide specifically binding to CD34 molecule and application thereof |
| CN105378063A (en) * | 2013-03-11 | 2016-03-02 | 泰加生物工艺学公司 | The production and use of red blood cells |
| US10087420B2 (en) | 2013-03-11 | 2018-10-02 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| US10206952B2 (en) | 2012-07-20 | 2019-02-19 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| CN109722414A (en) * | 2017-10-27 | 2019-05-07 | 博雅辑因（北京）生物科技有限公司 | It is a kind of efficiently to prepare the method for mature erythrocyte and be used to prepare the culture medium of mature erythrocyte |
| US10442853B2 (en) | 2008-05-16 | 2019-10-15 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| US10556006B2 (en) | 2008-08-28 | 2020-02-11 | Taiga Biotechnologies, Inc. | Compositions and methods for modulating an immune response |
| US10760055B2 (en) | 2005-10-18 | 2020-09-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
| US10864259B2 (en) | 2017-08-03 | 2020-12-15 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| US11116796B2 (en) | 2016-12-02 | 2021-09-14 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039628A1 (en) * | 1995-06-06 | 1996-12-12 | Stemcell Therapeutics L.L.C. | GLYCOPROTEIN gp105 ON BL3 HEMATOPOIETIC STEM CELLS |
| WO1999023207A1 (en) * | 1997-10-31 | 1999-05-14 | Fred Hutchinson Cancer Research Center | Monoclonal antibodies to canine cd34 |
| CA2386192A1 (en) * | 1999-10-07 | 2001-04-12 | Avi Biopharma, Inc. | C-myc antisense-treated hematopoietic stem cell composition and method |
-
2001
- 2001-09-21 CN CNB011418664A patent/CN100506978C/en not_active Expired - Lifetime
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10760055B2 (en) | 2005-10-18 | 2020-09-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
| US11667695B2 (en) | 2008-05-16 | 2023-06-06 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| US10442853B2 (en) | 2008-05-16 | 2019-10-15 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| US11369678B2 (en) | 2008-08-28 | 2022-06-28 | Taiga Biotechnologies, Inc. | Compositions and methods for modulating immune cells |
| US10556006B2 (en) | 2008-08-28 | 2020-02-11 | Taiga Biotechnologies, Inc. | Compositions and methods for modulating an immune response |
| US10206952B2 (en) | 2012-07-20 | 2019-02-19 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| US10953048B2 (en) | 2012-07-20 | 2021-03-23 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| CN105378063B (en) * | 2013-03-11 | 2019-02-05 | 泰加生物工艺学公司 | The generation and purposes of red blood cell |
| US10087420B2 (en) | 2013-03-11 | 2018-10-02 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| US10786534B2 (en) | 2013-03-11 | 2020-09-29 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| CN105378063A (en) * | 2013-03-11 | 2016-03-02 | 泰加生物工艺学公司 | The production and use of red blood cells |
| CN104862278A (en) * | 2014-02-26 | 2015-08-26 | 苏州方舟基因药业有限公司 | Isolated human hematopoietic stem cell amplification culture solution formula |
| CN104862278B (en) * | 2014-02-26 | 2018-07-10 | 苏州方舟基因药业有限公司 | A kind of in vitro human hematopoietic stem cell amplification cultivation formula of liquid |
| CN105254717B (en) * | 2015-08-18 | 2018-08-24 | 中山大学 | The polypeptide combined with CD34 molecular specificities and its application |
| CN105254717A (en) * | 2015-08-18 | 2016-01-20 | 广州一代医药科技有限公司 | Polypeptide specifically binding to CD34 molecule and application thereof |
| US11116796B2 (en) | 2016-12-02 | 2021-09-14 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| US10864259B2 (en) | 2017-08-03 | 2020-12-15 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| CN109722414A (en) * | 2017-10-27 | 2019-05-07 | 博雅辑因（北京）生物科技有限公司 | It is a kind of efficiently to prepare the method for mature erythrocyte and be used to prepare the culture medium of mature erythrocyte |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100506978C (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rothenberg et al. | Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. | |
| EP2882850B1 (en) | System for preparation of adipose-derived stem cells | |
| EP1028737B1 (en) | Human mesenchymal stem cells from peripheral blood | |
| US10967110B2 (en) | System and methods for preparation of adipose-derived stem cells | |
| CN102321573B (en) | Tangential flow filtration devices and methods for stem cell enrichment | |
| CN100506978C (en) | Hemapoietic stem/ancestral cell enriching method and its in vitro directional induction and differentiation | |
| AU5436998A (en) | MSC-megakaryocyte precursor composition and method of isolating MSCs asso ciated with isolated megakaryocytes by isolating megakaryocytes | |
| CN104845934A (en) | Mass preparation method for cord blood CD34+ hematopoietic stem cell-derived dendritic cells | |
| JPH09501324A (en) | Flow-through bioreactor with a groove for cell retention | |
| CN103484428B (en) | Applications of CAPE (Caffeic Acid Phenylethyl Ester) in culturing hematopoietic stem/progenitor cells in vitro | |
| WO2022198805A1 (en) | Method for inducing in vitro differentiation of hemopoietic stem cells into regulatory t cells | |
| CN1699557A (en) | Process for separation and culture of marrow mesenchyme stem cell | |
| CN114591910B (en) | Method for enriching cord blood hematopoietic stem cells by utilizing mesenchymal stem cells cultured in low-oxygen three-dimensional environment | |
| CN1746297A (en) | Placenta derived mesenchymal stem cell and preparation thereof | |
| CN112048474B (en) | Method for enhancing hematopoietic stem cell transplantation capability | |
| CN112011507B (en) | Method for separating peripheral blood mononuclear cells of anemic platelets | |
| CN1142270C (en) | Method of separating megakaryo archeocyte | |
| Stirling et al. | In vitro culture of artificial thrombi | |
| Skarlatos et al. | Accelerated development of human monocyte-macrophages cultured on Plastek-C tissue culture dishes | |
| CN1552848A (en) | CIK cell external culturing method | |
| WELLS | A new approach to the separation of cells at unit gravity | |
| CN117645973A (en) | New application of ascorbic acid and MYH9 protein | |
| Markham et al. | Preliminary observations on an isolate from synvoial fluid of patients with rheumatoid arthritis. | |
| Palsson et al. | Replating of bioreactor expanded human bone marrow results in extended growth of primitive and mature cells | |
| CN117757737A (en) | Preparation method of high-concentration mesenchymal stem cells, and related preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING JIACHENHONG BIOLOGICAL TECHNOLOGY CO., LTD Free format text: FORMER OWNER: FEILD FLOOD TRANSFUSION INST., ACADEMY OF MILITARY MEDICINE SCIENCES, PLA Effective date: 20100322 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100850 NO.27, TAIPING ROAD, HAIDIAN DISTRICT, BEIJING CITY TO: 100176 NO.4, YONGCHANG NORTH ROAD, BEIJING CITY ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, BEIJING CITY |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100322 Address after: 100176 No. 4 North Yongchang Road, Beijing economic and Technological Development Zone, Beijing Patentee after: Beijing Jia Chen Hong Biological Technologies Company Limited Address before: 100850 Taiping Road, Beijing, Haidian District, No. 27 Patentee before: Inst. of Field Blood Transfusion, Academy of Military Medical Sciences, PLA |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20090701 |